PATNA: The All India Institute of Medical Sciences-Patna (AIIMS-P) has completed the target of enrolling 1,000 volunteers for Phase 3 trial of Covaxin.
Doses of the indigenously developed Covid-19 vaccine candidate were administered to 108 people at the hospital on Wednesday. With this, altogether 1,080 volunteers have received shots of the intramuscular injection in the final phase of the multi-centric human trial so far.
In Phase 3, 50% participants will receive the vaccine and the remaining 50% a placebo.
AIIMS-P superintendent Dr C M Singh, who is also the principal investigator of the trial, told this newspaper that more volunteers were coming forward for the final trial of the vaccine.
“We have not received a single complaint from the volunteers, who were administered the first dose of Covaxin. They will be given the second dose after completion of their 28-day period this week. Later, follow-ups will be done on Days 28, 42, 104 and 194 to check their immunogenicity,” Singh said.
He added, “Our research officers keep in touch with the volunteers and interact with them twice a day over the phone.”